Pages that link to "Q29616719"
Jump to navigation
Jump to search
The following pages link to Comprehensive analysis of kinase inhibitor selectivity (Q29616719):
Displaying 50 items.
- High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines (Q23058134) (← links)
- Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms (Q24339394) (← links)
- Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach (Q24672143) (← links)
- Lung inflammation caused by inhaled toxicants: a review (Q26744356) (← links)
- Off-label use of targeted therapies in oncology (Q26747685) (← links)
- Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging (Q26768475) (← links)
- Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging (Q26774478) (← links)
- Ten things you should know about protein kinases: IUPHAR Review 14 (Q26849417) (← links)
- Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery (Q26853215) (← links)
- The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL (Q26866312) (← links)
- Bivalent inhibitors of protein kinases (Q26999008) (← links)
- Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? (Q27001584) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? (Q27026262) (← links)
- Developing irreversible inhibitors of the protein kinase cysteinome (Q27027983) (← links)
- STITCH 4: integration of protein-chemical interactions with user data (Q27136674) (← links)
- Using existing drugs as leads for broad spectrum anthelmintics targeting protein kinases (Q27336465) (← links)
- KinomeXplorer: an integrated platform for kinome biology studies (Q27495267) (← links)
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors (Q27673353) (← links)
- Affinity-Based Probes Based on Type II Kinase Inhibitors (Q27674665) (← links)
- Sequence Determinants of a Specific Inactive Protein Kinase Conformation (Q27678722) (← links)
- Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor (Q27679284) (← links)
- A Highly Selective Dual Insulin Receptor (IR)/Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor Derived from an Extracellular Signal-regulated Kinase (ERK) Inhibitor (Q27679510) (← links)
- A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity (Q27680722) (← links)
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (Q27681935) (← links)
- An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase (Q27682355) (← links)
- Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis (Q27684187) (← links)
- Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation (Q27698001) (← links)
- The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine (Q27700733) (← links)
- Comprehensive characterization of the Published Kinase Inhibitor Set (Q27702518) (← links)
- Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity (Q27704055) (← links)
- Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib (Q27704282) (← links)
- Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles (Q27727987) (← links)
- Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML (Q27852275) (← links)
- A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity (Q27852979) (← links)
- Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. (Q27853122) (← links)
- Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors (Q27853214) (← links)
- Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4 (Q28078574) (← links)
- Targeting the TAM Receptors in Leukemia (Q28078654) (← links)
- Development of novel ACK1/TNK2 inhibitors using a fragment-based approach (Q28257452) (← links)
- ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion (Q28390371) (← links)
- What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics? (Q28484296) (← links)
- Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways (Q28533401) (← links)
- Bioorthogonal small molecule imaging agents allow single-cell imaging of MET (Q28535045) (← links)
- Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks (Q28537891) (← links)
- Identification of distant drug off-targets by direct superposition of binding pocket surfaces (Q28538129) (← links)
- A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination (Q28539535) (← links)
- Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use (Q28541231) (← links)
- c-Src binds to the cancer drug Ruxolitinib with an active conformation (Q28542851) (← links)
- Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors (Q28546245) (← links)